Netflix Uses Queensland’s Third Feature Film to Make the Most of its Incentives

Netflix, the streaming giant, is taking advantage of government incentives and preparing for another Queensland production to film on the Gold Coast. This will be its third production in the last year.

Hoodlum Entertainment in Brisbane will produce the feature film. It stars Victoria Justice, an American singer/actor, and Adam Demos, from Australia.

This announcement follows recent Netflix Original productions Escape from Spiderhead starring Chris Hemsworth and True Spirit, a Jessica Watson biopic being shot on the Gold Coast.

Screen Queensland’s production incentive will allow for $8 million in local economic development and 120 jobs to be created.

The film is yet to be titled and centres on Justice as an American wine importer who travels to Australia to find the Australian charms of Demos. Demos has starred in Sex/Life, Falling In Love, and other Netflix originals.

Justice made his first appearance on Nickelodeon 15 years ago as Lola Martinez, a comedy-drama show. Since 2009, Demos has been a regular guest on Australian screens. He was most recently seen in Janet King or Unreal.

Kylie Munnich, CEO Screen Queensland, says that Netflix’s repeat business reflects Queensland’s’strength, competitiveness’ and its incentives, locations, skilled crew, and post-production facilities.

“We are thrilled to see Hoodlum produce this global feature film and proud to support all three seasons Hoodlum’s ABC crime series Harrow and their celebrated 2018 Netflix Original series Tidelands. We also supported their comedic First Nations coproduction All My Friends Are Racist.

“Screen Queensland is succeeding with our mission to promote Queensland’s status as a global production center that can provide local productions and international productions exactly what they need in order to produce high-quality content for global audiences.”

Other Queensland Government-funded productions are currently being shot at Screen Queensland Studios, Brisbane. They also film the new ABC crime series Troppo.

Annastacia Palaszczuk, Queensland Premier, said that the new Netflix movie is just one of a number of international and domestic productions continuing to fuel Queensland’s screen boom.

“This project is an excellent example of how Queensland’s Production Attraction Strategy benefits Queensland’s local screen sector through exciting co-production agreements for local businesses, like Hoodlum Entertainment, one the state’s most successful producers.”

The Queensland Government announced in June a $71million boost to the local film industry. This includes $53 million for production attraction strategies.

New figures today reveal that the subscription video-on-demand (SVOD) sector is a major source of investment in Australian content.

The first SVOD Australian content investment report, published by the Australian Communications and Media Authority, (ACMA), shows that Amazon Prime and Disney, Netflix, Stan and Stan spent over $150 million on Australian programs between 2019-20.

Even more is the cost of productions shot in Australia, but not here. This adds up to $115million over the same period. Clickbait, a $50 million production was filmed in Melbourne.

This brings the total investment in Australian-related content and Australian-related content via SVODs up to $268 million.

The report shows the increasing demand for local content both domestically and internationally. There are over 3,000 hours worth of Australian content available from more than 600 programs on the four services.

Paul Fletcher (Federal Minister for Communications, Urban Infrastructure and Cities), says that “What we know is that we have an adequate starting point in terms content, a good footprint abroad, and that more that 80% of the $153m expenditure was on co-commissioning or commissioning new Australian programs.”

Federal incentives include an increase in Producer Offset rates for television content, from 20% to 30% to encourage SVOD productions.

In 2021-22, Screen Australia and Australia’s Children’s Television Foundation will receive $110 million to help develop and produce Australian drama, documentary, and children’s content on film and television.

nasal swabs

Rhinomed Shares up 82% Thanks to Patented COVID Nasal Swabs

Rhinomed shares (ASX: RNO), which are now trading at 82%, have increased their price after the wearable nose and respiratory technology company received orders from the NSW Government to purchase its self-administered nasal strips.

As part of a program supporting testing capability, the group began supplying NSW Health Pathology an initial 1 million Rhinoswabs.

These orders will be fulfilled in the coming weeks. Rhinomed is currently expanding its manufacturing capabilities to meet growing demand domestically and internationally for its innovative technology.

These are the company’s strengths: The ease and comfort of the swabs and the ability to capture larger samples and speed up the collection process. This significantly reduces waiting times.

It works with existing polymerase chains reaction (PCR) pathology workflows. The technology is comparable in cost and quality to standard care nasopharyngeal samples from the US and Europe.

Rhinomed CEO Michael Johnson said, “We are delighted to receive this support für this Australian innovation.”

The Rhinoswab is able to make a significant impact on the SARS/CoV-2 testing process, and allow more people to be tested quickly.

“With nearly two billion SARS-CoV-2 test performed worldwide in the past 18 months, including close to 26 million* in Australia, there’s a huge opportunity for Rhinoswab. This will allow them to dramatically improve the testing process and clinical outcomes.

This announcement contrasts sharply with where Rhinomed was in August 2020. Its shares had fallen by three quarters the previous year. Rhinomed had placed its hopes on a vaporizer for medicinal cannabis, despite the fact that Pronto Sleep was being commercialized in the United States. This was a declining market.

Just as the company’s leadership had taken advantage of the booming medical cannabis market in 2018, it announced in September 2020 the realization of a logical COVID pivot; not only an intention but also the declaration of advanced technology for a nasal swab that can take samples from the nose to determine if there are any upper respiratory tract diseases. The shares rose 50 per cent in one day from 8cps and 12cps.

Johnson stated that Johnson was proving the point that mass, high-frequency testing could prove to be an important tool for managing epidemics, pandemics, and other infectious disease outbreaks.

“Rhinomed believes a simple, effective and comfortable nasal swab, that anyone can use every day, could be a key to achieving this goal.”

He stated that the company was quickly looking for manufacturing solutions and would soon register the device in Australia and the USA. All these goals were achieved in less than a year. Rhinoswab has been registered with the US Food and Drug Administration, the Australian Therapeutic Goods Association and a European CE (Conformite Europaenne) mark.

Today’s news brought RNO shares to $0.365 per share. Revenue from the initial order is expected to represent 25-35% of FY21 unaudited revenues of $3.9million. The company’s market capitalisation stands at over $92 million as of the writing. This is a clear sign that investors believe profits will follow.

The interim results of a comparison study with 204 participants at CWZ, Radboud University Medical Center and a leading teaching hospital Nijmegen, the Netherlands, were in line with previous user study results. Participants showed a strong preference for Rhinoswab over the traditional nasal swab.

  • 98% of respondents preferred Rhinoswab over the Nasopharyngeal Swab
  • 98% of Rhinoswab users felt no pain, compared to 48% with Nasopharyngeal Swab.
  • 98% of respondents said they needed very little to no guidance while using Rhinoswab.